

Cover Story
News Analysis
By Jacquelyn Cobb and Sara Willa Ernst
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Sponsored
By John’s Hopkins Kimmel Cancer Center Communications
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for March
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CDC’s recommendation to delay infant hepatitis B shot is likely to raise infections, JAMA studies show
- CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
















